Alemtuzumab Therapy for Leukemic Cutaneous T-Cell Lymphoma: Diffuse Erythema As a Positive Predictor of Complete Remission

Supplementary Online Content

Watanabe R, Teague JE, Fisher DC, Kupper TS, Clark RA. Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission. Published online April 23, 2014. JAMA Dermatology. doi:10.1001/jamadermatol.2013.10099.

eTable 1. Patient Characteristics

This supplementary material has been provided by the authors to give readers additional information about their work.

Downloaded From: https://jamanetwork.com/ on 09/25/2021

Supplemental Material

eTable 1 Patient Characteristics Disease Age Clinical WHO/ TNM duration Response to LDA (blood/skin: Gender manifestations EORTC stage (years) Previous Tx duration) Final outcome nbUVB PUVA I B D deceased from lung infection post 60s M DE SS III 9 SS CR/CR: 1 mo XRT 60s M DE SS IVA 14 I P V B D G SS CR/CR: 26 mo CD52 loss PD 70s F DE SS IVA 6 I P V B D PUVA CR/CR: 30 mo 17 mo CR after 2nd LDA 60s M DE SS III 5 I P V B D G PUVA CR/CR: 24 mo 15 mo CR after 2nd LDA 50s M DE SS IVA 3 I P V B CR/CR: 9 mo CD52 loss PD with D G I P B GND PUVA 60s M DE SS IVA 2 nbUVB CR/CR: 59 mo with SCT CR 70s M DE SS IVA 7 I P B D CR/CR: 8 mo CD52 loss PD with P G R B 70s M DE SS IVA 8 I P B TS nbUVB CR/CR: 27 mo 5 mo CR after 2nd LDA 50s M DE SS IVA 4 SCT DLI G CR/CR: 11 mo with DLI PR with Brentuximab I P V TS PUVA 60s F DE SS IVA 1 nbUVB CR/CR: 43 mo CR 80s M DE SS IVA 1 I P CR/CR deceased due to unknown reason 80s F DE SS IVA 1 B D SS TS CR/CR: 6 mo PD no more tx 70s M DE SS III 1 nbUVB CR/CR: 4 mo CD52 loss CR:30 mo /PR with NM TS 70s M DE SS III 5 I P B brachytherapy TSEB CR/PR 60s F DE SS IVA 2 I P CR/CR: 36 mo with brachytherapy CR 60s F DE SS IVA 2 I P V B CR/CR: 36 mo with TSEB CR 60s F DE SS III 3 SS CR(21 mo)/PR with TS deceased due to other reason 70s M DE/P/T B-MF* IVA 1 I P B CR/PD-->CR: 7 mo with TSEB deceased due to disease 50s F P/T B-MF* IVA 2 P SS TS CR/CR: 24 mo with TSEB SCT CR 50s F P/T B-MF* IVA 16 I P B D SS PR/PD deceased due to disease 60s M P/T/DE SS IVA 1 I P V G D GND SCT PR/PD deceased due to GVHD 60s M P/T B-MF* IVA 3 I P D G TS CR(1 mo)/PD-LCT deceased due to diesease 40s M P/T B-MF* IVA 1 SS TS CR(1 mo)/PD-LCT G SCT deceased due to GVHD *The current WHO/EORTC classification designates all patients with less than erythrodermic disease and blood involvement as MF with Blood involvement (B-MF). However, these patients had leukemic disease at the time of presentation, no prior history of MF and T cells with a central memory phenotype.

DE=diffuse erythema, P=patches/plaques, T=tumors I: IFN-α2a, P: extracorporeal photochemotherapy, V: vorinostat, B: bexarotene: D: denileukin diftitox, G: gemcitabine, D: doxorubicin, GND: gemcitabine/nevelbine/doxorubicin, R: Romidepsin, TS: topical steroids, SS: systemic steroids, NM: nitrogen mustard, HSCT: hematopoietic stem cell transplantation DLI: donor lymphocyte infusion, TSEB: total skin electron beam, CR: complete remission, PR: partial remission, PD: persistent disease, LCT: large cell transformation

Downloaded From: https://jamanetwork.com/ on 09/25/2021